Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round...